| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Arand, M., et al.
(författare)
-
The telltale structures of epoxide hydrolases
- 2003
-
Ingår i: Drug metabolism reviews (Softcover ed.). - 0360-2532 .- 1097-9883. ; 35:4, s. 365-383
-
Tidskriftsartikel (refereegranskat)abstract
- Traditionally, epoxide hydrolases (EH) have been regarded as xenobiotic-metabolizing enzymes implicated in the detoxification of foreign compounds. They are known to play a key role in the control of potentially genotoxic epoxides that arise during metabolism of many lipophilic compounds. Although this is apparently the main function for the mammalian microsomal epoxide hydrolase (mEH), evidence is now accumulating that the mammalian soluble epoxide hydrolase (sEH), despite its proven role in xenobiotic metabolism, also has a central role in the formation and breakdown of physiological signaling molecules. In addition, a certain class of microbial epoxide hydrolases has recently been identified that is an integral part of a catabolic pathway, allowing the use of specific terpens as sole carbon sources. The recently available x-ray structures of a number of EHs mirror their respective functions: the microbial terpen EH differs in its fold from the canonical α/β hydrolase fold of the xenobiotic-metabolizing mammalian EHs. It appears that the latter fold is the perfect solution for the efficient detoxification of a large variety of structurally different epoxides by a single enzyme, whereas the smaller microbial EH, which has a particularly high turnover number with its prefered substrate, seems to be the better solution for the hydrolysis of one specific substrate. The structure of the sEH also includes an additional catalytic domain that has recently been shown to possess phosphatase activity. Although the physiological substrate for this second active site has not been identified so far, the majority of known phosphatases are involved in signaling processes, suggesting that the sEH phosphatase domain also has a role in the regulation of physiological functions.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
|
|
| 17. |
- Desbans, Coraline, et al.
(författare)
-
Accurate prediction of variability in CLint and Fm via 3A4 is only obtained by assessing a series of individual cryopreserved human hepatocyte batches
- 2010
-
Ingår i: Drug metabolism reviews (Softcover ed.). - New York : Informa Healthcare. - 0360-2532 .- 1097-9883. ; 42:Suppl. 1, s. 274-274
-
Tidskriftsartikel (refereegranskat)abstract
- Multiple in-vitro and in-vivo methods are currently assessed and under discussion to predict human clearance and pharmacokinetics from preclinical studies. A combination of high fm with a high fraction metabolism via a single pathway, e.g. via CYP3A4 (fmCYP3A4), has been recognized as a high risk factor for Drug Drug Interactions (DDI) in the clinical setting[1],[2],[3],[4] . Thus, an early predictive tool to allow for appropriate modeling of this potential risk for DDI is highly warranted. Hepatocytes, capable of both phase I and phase II reactions, are an attractive system to study fraction metabolized (fm) via a single pathway. In the present study, intrinsic clearance (CLint) was determined in cryopreserved human hepatocytes in suspension for a set of five compounds with known and variable fm via CYP3A4 (amitriptyline, loratadine, methylprednisolone, midazolam, and tacrolimus) in the absence or presence of ketoconazole. In order to get an insight into the influence of inter-individual variability, twelve batches of cryopreserved human hepatocytes with either high, moderate or low CYP3A4-dependent activity towards midazolam (MDZ) were chosen. Clint values were determined as substrate depletion under shaking conditions (900rpm) using an elliptic shaker as previously reported[5]. For all compounds, the mean CLint for individual donors in absence of ketoconazole correlated very well with literature data on the mean of individual donors1,2,3, and/or pools of donors5. Average fmCYP3A4 for midazolam was 83%, tacrolimus 64%, methylprednisolone 55%, amitriptyline 28%, and loratadine 19% are also well within the literature data2,3,4. Interestingly, the results obtained for a homogenous subpopulation regarding MDZ CLint and percent inhibition by ketoconazole, were not directly related to the ketoconazole sensitive CLint for the other CYP3A4 substrates tested. The variability in CYP3A4 contribution for compounds having multiple metabolic pathways cannot be predicted by the fm3A4 for MDZ. This suggests that an overall prediction of CLint or fm via CYP3A4 for compounds partially metabolized by this enzyme is not possible. Thus, the individual differences in CLint for a given compound and fmCYPi can only be well covered by assessing a series of individual cryopreserved human hepatocyte batches.[1] Lu, C., Miwa, G. T., Prakash, S. R., Gan, L-S. and Balani, S. K. (2007), Drug Metabolism And Disposition, 35: 1, 79–85[2] Lu, C., Hatsis,P., Berg,C., Lee, F. W. and Balani, S. K. (2008), Drug Metabolism And Disposition, 36: 7, 1255–1260[3] Lu, C., Hatsis,P., Berg,C., Lee, F. W. and Balani, S. K. (2008), Drug Metabolism And Disposition, 36: 7, 1261–1266[4] Emoto, C., Murase, S. and Iwasaki, K.(2006), Xenobiotica, 36: 8, 671 — 683[5] Simon ,S., Blanchard, N., Alexandre, E., Hewitt, N. J., Bachellier, P., Heyd, B., Coassolo, P., Schuler, F., Richert, L., (2009) ‘MV-HUF Copenhagen’
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
| 26. |
|
|
| 27. |
|
|
| 28. |
- Ingelman-Sundberg, M
(författare)
-
Functions of minor cytochrome P450s
- 2006
-
Ingår i: DRUG METABOLISM REVIEWS. - 0360-2532. ; 38, s. 4-5
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
- Ingelman-Sundberg, M
(författare)
-
PHARMACOGENETICS OF PROTEIN DRUGS
- 2008
-
Ingår i: DRUG METABOLISM REVIEWS. - 0360-2532. ; 40, s. 29-29
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 33. |
- Jiye, A, et al.
(författare)
-
Global analysis of low-molecular-weight compounds in human plasma using GC/TOF-MS
- 2004
-
Ingår i: DRUG METABOLISM REVIEWS. - 0360-2532. ; 36, s. 246-246
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- We developed a method for analysis of low-molecular-weight compounds (LMWC) in human plasma involving extraction of metabolites by organic solvents, derivatization of extract and final analysis by GC/TOF-MS. The overall strategy for the development of the method was based on using design-of-experimental (DOE), and data evaluation based on multivariate statistical tools like PCA and PLS. The results showed that the extraction efficiency for different solvents varied, and that methanol was important for high reproducibility. More than 300 compounds could be detected in one analysis. Forty five of them were identified, including amino acids, lipids and free fatty acids, organic acids, carbohydrates and so on. The quantitative data of these metabolites showed, with two exceptions, high precision and good linearity between response and concentration. By using this method it is now possible to analyze plasma samples with high throughput to identify metabolic biomarkers for different kinds of diseases.
|
|
| 34. |
|
|
| 35. |
- Jones, Wayne A
(författare)
-
Profiles in drug metabolism and toxicology: Richard Tecwyn Williams (1909-1979)
- 2015
-
Ingår i: Drug metabolism reviews (Softcover ed.). - : TAYLOR & FRANCIS LTD. - 0360-2532 .- 1097-9883. ; 47:4, s. 401-405
-
Forskningsöversikt (refereegranskat)abstract
- This article pays homage to the life and work of a veritable pioneer in toxicology and drug metabolism, namely a Welshman, Richard Tecwyn Williams, FRS. Professor Williams, or RT as he was known, made major contributions to knowledge about the metabolism and toxicology of drugs and xenobiotics during a scientific career spanning nearly 50 years. Author or coauthor of close to 400 research articles and reviews, including a classic book, entitled Detoxication Mechanisms, Williams and his research school investigated virtually all aspects of drug metabolism, especially conjugations. In particular, the concepts of phase 1 and phase II metabolic pathways were introduced by Williams; the biliary excretion of drugs was extensively studied as were species differences in drug metabolism and detoxication. Besides investigating the metabolism of many pharmaceutical drugs, such as sulfonamides and thalidomide, Williams and his group investigated the disposition and fate in the body of organic pesticides and recreational drugs of abuse, such as amphetamine, methamphetamine and lysergic acid diethylamide (LSD).
|
|
| 36. |
|
|
| 37. |
|
|
| 38. |
|
|
| 39. |
|
|
| 40. |
|
|
| 41. |
|
|
| 42. |
|
|
| 43. |
|
|
| 44. |
|
|
| 45. |
|
|
| 46. |
|
|
| 47. |
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
|
|
